Physician profile
Omar Shamsi
NPI 1053599233
$38,844.19
in general payments reported to CMS, 2019-2025
23 companies · $30K in 2025
The $30K reported for 2025 was more than what 91% of Obesity Medicine (Internal Medicine) providers received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,951 · 2020: $914 · 2021: $1,239 · 2022: $547 · 2023: $1,350 · 2024: $1,994 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $4,549 · Travel and Lodging: $2,364 · Consulting Fee: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,150.00 |
| Food and Beverage | $4,549.45 |
| Travel and Lodging | $2,364.09 |
| Consulting Fee | $2,130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27,575.76 | 2023-2025 | Zepbound, Mounjaro, Trulicity |
| Novo Nordisk INC | $7,013.86 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Endo Pharmaceuticals INC. | $614.27 | 2019-2023 | Nascobal |
| Aimmune Therapeutics, INC. | $545.94 | 2024-2025 | Zenpep |
| Abbvie INC. | $519.72 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $339.94 | 2020-2023 | Trintellix |
| Bausch Health US, LLC | $307.93 | 2019-2023 | Wellbutrin, Aplenzin |
| Currax Pharmaceuticals LLC | $244.59 | 2019-2025 | Contrave, Nexletol, Nexlizet |
| Xeris Pharmaceuticals, INC. | $195.54 | 2023-2024 | Gvoke Hypopen |
| Jazz Pharmaceuticals INC. | $182.96 | 2021-2022 | |
| Shire North American Group INC | $166.11 | 2019 | |
| Kvk-Tech, INC. | $140.06 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $136.61 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $129.24 | 2021-2023 | Imcivree |
| Amarin Pharma, INC. | $122.09 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $111.24 | 2025 | Voquezna |
| Corcept Therapeutics | $102.90 | 2023-2024 | Korlym |
| Upsher-Smith Laboratories LLC | $95.84 | 2019 | |
| Eisai INC. | $87.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.01 | 2019-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $63.88 | 2024-2025 | Auvelity |
| Abbott Laboratories | $59.97 | 2025 | Freestyle Libre 3 |
| Nalpropion Pharmaceuticals LLC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Shamsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.